Stomach Cancer Trial, Recruiting NCT07069842 Sponsor: Changzhi People's Hospital Affiliated to Changzhi Medical College Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT07069842
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 who have been diagnosed with advanced stomach cancer or cancer at the junction of the stomach and oesophagus that cannot be surgically removed, or that has spread to other parts of the body, confirmed by laboratory tissue testing.
  • People who are planned to receive a first course of treatment combining immunotherapy drugs with chemotherapy, with or without a targeted therapy that works against the HER2 protein.
  • People who have at least one area of cancer that can be measured on scans according to specific research guidelines, and whose general physical wellbeing falls within an accepted range on a standard activity scale (confirm with trial site).

Who may not be able to join:

  • People who have had another type of cancer within the 3 years before the study begins, or who have cancer that has spread to the brain or the lining around the brain or spinal cord.
  • People who have other health conditions that, in the treating doctor's judgement, could seriously affect their safety or prevent them from completing the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jun Zhao, Changzhi People's Hospital

Phone: +86-13509754125

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Changzhi People's Hospital Affiliated to Changzhi Medical College
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Response to Immunotherapy in Solid Tumors

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov